{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:05:02Z","timestamp":1790791502013,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Astellas Pharma Inc."},{"name":"Astex Pharmaceuticals Inc."},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol Myers Squibb"},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008422","name":"Endocyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Incyte"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PharmaMar"},{"name":"Prima Biomed"},{"name":"Roche\/Genentech"},{"name":"TapImmune"},{"name":"TESARO"},{"name":"Acceleron Pharma"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AstraZeneca\/MedImmune"},{"name":"Eureka Therapeutics"},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leadiant Biosciences"},{"name":"MedPacto Inc."},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010293","name":"Seattle Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010293","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tracon Pharma"},{"DOI":"10.13039\/100006510","name":"Duke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AbbieVie"},{"name":"Millenium"},{"name":"Cerulean"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tesaro"},{"name":"Morab"},{"name":"Ludwig"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Duke University Division of Gynecologic Oncology"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ygyno.2019.03.246","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T09:52:59Z","timestamp":1553766779000},"page":"555-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0946-7662","authenticated-orcid":false,"given":"Angeles Alvarez","family":"Secord","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McCollum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany A.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Broadwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Squatrito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Havrilesky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.","family":"Gabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Starr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Chris","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda R.","family":"Duska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.03.246_bb0005","doi-asserted-by":"crossref","unstructured":"Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol.. 2007;25(33):5165-71. doi:https:\/\/doi.org\/10.1200\/JCO.2007.11.5345. PubMed PMID: 18024863.","DOI":"10.1200\/JCO.2007.11.5345"},{"issue":"26","key":"10.1016\/j.ygyno.2019.03.246_bb0010","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ygyno.2019.03.246_bb0015","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.ygyno.2019.03.246_bb0020","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.03.246_bb0025","doi-asserted-by":"crossref","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J. Clin. Oncol.. 2014;32(13):1302-8. doi:https:\/\/doi.org\/10.1200\/JCO.2013.51.4489. PubMed PMID: 24637997.","DOI":"10.1200\/JCO.2013.51.4489"},{"issue":"6","key":"10.1016\/j.ygyno.2019.03.246_bb0030","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2019.03.246_bb0040","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1172\/JCI70212","article-title":"Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer","volume":"123","author":"Welti","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ygyno.2019.03.246_bb0045","doi-asserted-by":"crossref","unstructured":"Boehringer Ingelheim GmbH Investigator's Brochure. Doc. No: U02-1482-11 Project No. 1199.P1\/1199.P2\/1199.P4\/1199.P5 Date of IB: 11 April 2011 Version No. 11.","DOI":"10.1055\/s-0031-1289213"},{"issue":"1","key":"10.1016\/j.ygyno.2019.03.246_bb0050","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","article-title":"Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"17","author":"du Bois","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2019.03.246_bb0055","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 2009;45(2):228-47. doi:https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026. PubMed PMID: 19097774.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"10.1016\/j.ygyno.2019.03.246_bb0060","doi-asserted-by":"crossref","unstructured":"Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J. Natl. Cancer Inst.. 2004;96(6):487-8. PubMed PMID: 15026475.","DOI":"10.1093\/jnci\/djh081"},{"key":"10.1016\/j.ygyno.2019.03.246_bb0065","doi-asserted-by":"crossref","unstructured":"Liu Y, Starr MD, Brady JC, Rushing C, Pang H, Adams B, Alvarez D, Theuer CP, Hurwitz HI, Nixon AB. Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105. Mol. Cancer Ther.. 2018;17(10):2248-56. doi:https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0916. PubMed PMID: 29997150.","DOI":"10.1158\/1535-7163.MCT-17-0916"},{"issue":"2","key":"10.1016\/j.ygyno.2019.03.246_bb0070","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cam4.71","article-title":"Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab","volume":"2","author":"Liu","year":"2013","journal-title":"Cancer Med."},{"issue":"9","key":"10.1016\/j.ygyno.2019.03.246_bb0075","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1002\/cam4.806","article-title":"Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)","volume":"5","author":"Hatch","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.ygyno.2019.03.246_bb0080","doi-asserted-by":"crossref","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials. 1989;10(1):1-10. PubMed PMID: 2702835.","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"10.1016\/j.ygyno.2019.03.246_bb0085","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1200\/JCO.2018.36.15_suppl.5506","article-title":"Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17","volume":"36","author":"Pignata","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.ygyno.2019.03.246_bb0090","doi-asserted-by":"crossref","first-page":"6957","DOI":"10.1158\/1078-0432.CCR-13-0926","article-title":"Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance)","volume":"19","author":"Nixon","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2019.03.246_bb0095","doi-asserted-by":"crossref","unstructured":"Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol.. 2012;13(8):827-37. doi:https:\/\/doi.org\/10.1016\/S1470-2045(12)70241-3. PubMed PMID: 22759480.","DOI":"10.1016\/S1470-2045(12)70241-3"},{"issue":"3","key":"10.1016\/j.ygyno.2019.03.246_bb0100","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/annonc\/mdx767","article-title":"Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study","volume":"29","author":"Tabernero","year":"2018","journal-title":"Ann. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2019.03.246_bb0105","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1200\/JCO.2016.34.15_suppl.5521","article-title":"Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin\u2013paclitaxel (CP)\u202f\u00b1\u202fbevacizumab (BEV): Results from GOG-0218","volume":"34","author":"Alvarez Secord","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.03.246_bb0110","doi-asserted-by":"crossref","unstructured":"Wang Y, Li L, Guo X, Jin X, Sun W, Zhang X, Xu RC. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine. 2012;59(2):228-36. Epub 2012\/05\/19. doi:https:\/\/doi.org\/10.1016\/j.cyto.2012.04.020. PubMed PMID: 22595649.","DOI":"10.1016\/j.cyto.2012.04.020"},{"issue":"25","key":"10.1016\/j.ygyno.2019.03.246_bb0115","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.2174\/138161212802002797","article-title":"Interleukin-6\/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer","volume":"18","author":"Dijkgraaf","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"15","key":"10.1016\/j.ygyno.2019.03.246_bb0120","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1200\/jco.2013.31.15_suppl.4520","article-title":"Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206","volume":"31","author":"Nixon","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2019.03.246_bb0125","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamaoncol.2017.4218","article-title":"Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial","volume":"4","author":"Richardson","year":"2018","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2019.03.246_bb0130","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/sj.bjc.6600701","article-title":"Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma","volume":"88","author":"Yokoyama","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"34","key":"10.1016\/j.ygyno.2019.03.246_bb0135","doi-asserted-by":"crossref","first-page":"57327","DOI":"10.18632\/oncotarget.16905","article-title":"Prognositic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2019.03.246_bb0140","doi-asserted-by":"crossref","unstructured":"Ghalamfarsa G, Rastegari A, Atyabi F, Hassannia H, Hojjat-Farsangi M, Ghanbari A, Anvari E, Mohammadi J, Azizi G, Masjedi A, Yousefi M, Yousefi B, Hadjati J, Jadidi-Niaragh F. Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice. J. Cell. Physiol.. 2018;233(10):7165-77. doi:https:\/\/doi.org\/10.1002\/jcp.26743. PubMed PMID: 29741783.","DOI":"10.1002\/jcp.26743"},{"key":"10.1016\/j.ygyno.2019.03.246_bb0145","doi-asserted-by":"crossref","first-page":"326","DOI":"10.12688\/f1000research.11771.1","article-title":"The role of tumor microenvironment in resistance to anti-angiogenic therapy","volume":"7","author":"Ma","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.ygyno.2019.03.246_bb0150","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/bs.ircmb.2016.09.007","article-title":"Immunomodulatory Activity of VEGF in Cancer","volume":"330","author":"Lapeyre-Prost","year":"2017","journal-title":"Int. Rev. Cell Mol. Biol."},{"issue":"5","key":"10.1016\/j.ygyno.2019.03.246_bb0155","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581930441X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581930441X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:43:21Z","timestamp":1758771801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581930441X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S009082581930441X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.246","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}